Navigation Links
Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis

primary objective of the study is to evaluate the safety of repeated exposure to aztreonam lysine for inhalation in people with CF. Each patient's participation in the study will last up to 18 months. Patients will receive treatment with 75 mg of aztreonam lysine for inhalation with the same regimen they received in AIR-CF1 or AIR-CF2 (BID or TID daily).

About Aztreonam Lysine for Inhalation

Aztreonam lysine for inhalation is an antibiotic candidate currently being studied in Phase III clinical trials as a treatment for people with CF who have pulmonary P. aeruginosa. Aztreonam has potent activity against Gram-negative bacteria such as P. aeruginosa. Aztreonam formulated with arginine is a FDA-approved agent for intravenous administration. Aztreonam lysine for inhalation is a proprietary inhaled formulation of aztreonam and has been granted orphan drug designation in the United States and Europe.

About PARI Pharma and the eFlow Electronic Nebulizer

Aztreonam lysine for inhalation is delivered by a novel inhalation device, the eFlow Electronic Nebulizer, developed by PARI Pharma GmbH. eFlow is a quiet, portable nebulizer that enables efficient aerosolization of liquid medications via a vibrating, perforated membrane. PARI Pharma also contributed to the development and optimization of the drug formulation (aztreonam lysine for inhalation) for delivery via eFlow. Based on PARI's 100-year history working with aerosols, PARI Pharma is dedicated to advancing inhalation therapies by developing innovative delivery platforms and new pharmaceutical formulations that work together to improve patient care.

About Cystic Fibrosis

Today, more than 30,000 people in the United States have CF. CF is a chronic, debilitating genetic disease. A major characteristic of CF is production of abnormally thick, sticky mucus in the lungs, trapping bacteria and predisposing patients to lung infections, which continually damage their lungs. Pulmonary in
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
2. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
3. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
4. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
5. Gilead Announces Presentation of Positive Phase III Data on Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
6. Data from Preclinical Studies of Gilead Nucleotide Compound GS 9219 to be Presented at AACR
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:4/21/2015)... MONROVIA, Calif. , April 21, 2015 ... developer, manufacturer and marketer of implantable lenses and delivery ... of Directors has appointed J. Steven Roush , ... total number of members on STAAR,s Board to seven.Mr. ... reporting agencies expertise, largely gained over a 39 year ...
(Date:4/21/2015)... and CAMBRIDGE, Mass. ... ( Tokyo : 4503) and Potenza ... of immuno-oncology programs, today announced an exclusive research ... is to advance a portfolio consisting of programs ... pathways, co-stimulatory signals and regulatory T cells. The ...
(Date:4/21/2015)... TOKYO , April 21, 2015 /PRNewswire/ ... conferences, has just announced Medtech Partnering Forum 2015 ... technology industry. The event, held May 28–29 in ... international medtech partnering conference in Japan ... new developments in the rapidly changing medical technology industry ...
Breaking Medicine Technology:J. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors 2J. Steven Roush, CPA Appointed to STAAR Surgical Board of Directors 3Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics 2Astellas Pharma And Potenza Therapeutics Partner To Build A Portfolio Of Immuno-Oncology Therapeutics 3Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 2Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 3Inaugural Medtech Partnering Forum to feature leading global medtech decision makers this May 28-29, 2015 in Tokyo, Japan 4
... Feb. 9, 2011 GeoVax Labs, Inc. (OTC Bulletin ... develops and tests innovative HIV/AIDS vaccines, announced today the ... Alabama Vaccine Research Clinic (AVRC) of the University of ... therapeutic vaccine trial. Although the GeoVax vaccines are currently ...
... The Covaris® LE220™ high performance ultra-sonicator has received ... at the LabAutomation 2011 conference in Palm Springs ... laboratory automation conference and exhibition, bringing science, technology, and ... LabAutomation are evaluated by a team of industry experts. ...
Cached Medicine Technology:GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 2GeoVax Launches a Second Clinical Site to Test the Therapeutic Benefit of its HIV Vaccine 3Covaris Receives the Society for Laboratory Automation and Screening (SLAS) New Product Award at LabAutomation 2011 2
(Date:4/21/2015)... Displays & Exhibits, Inc. a division ... show exhibit building industry, announced a management change of ... Absolute Exhibits in Tustin, California.“It is very important to ... the variation in quality as offered by overseas trade ... Adduru. Mr. Adduru is the new manager of Displays ...
(Date:4/21/2015)... 2015 On April 2, 2015, Elle ... Achieve Kylie Jenner Lips With Disastrous Results,” ... themselves while attempting an at-home lip augmentation ... that creating an airlock around one’s mouth for several ... and achieve Kylie Jenner’s now famous pout. (see: goo.gl/dFQW2L) ...
(Date:4/21/2015)... 21, 2015 Top medical tourism firm, ... for their ongoing commitment to providing superior patient experiences. ... provide patients with the best possible experience for a ... and body. , Executives at Ojas Aesthetic Clinic persistently ... of — nothing about you, without you — through ...
(Date:4/21/2015)... 2015 AvePoint, the established ... today announced a new enhancement to DocAve Policy ... Office 365 Management Activity API. This integration creates a ... and take action on all events that take place ... 365 Management Activity API provides customers with greater transparency ...
(Date:4/21/2015)... 2015 Lyft has announced the ... otolaryngologists, bringing the most advanced speech-recognition technology to ... Otolaryngologists can now experience the full benefits of ... in the industry, Lyft, which offers value-added support ... , “Lyft is very excited to be able ...
Breaking Medicine News(10 mins):Health News:Displays & Exhibits Reveals Tustin, California Showroom Under New Management 2Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 2Health News:VisitandCare.com Cosmetic Surgery Provider in India Earns Recognition for Patient Satisfaction 3Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 2Health News:AvePoint Integrates Microsoft Office 365 Management Activity API into DocAve Policy Enforcer for Proactive SharePoint Monitoring 3Health News:Lyft Expands Its Offerings to Include Dragon® Medical Practice Edition 2 for Otolaryngologists. 2
... of two proteins in mammalian embryos prevents the development ... at the Medical College of Wisconsin, Milwaukee, has found. ... issue of Developmental Biology, was led by Stephen Duncan, ... the Medical College. , This is the first study ...
... second monoclonal antibody drug to chemotherapy looks promising for ... Clinic researchers working with the North Central Cancer Treatment ... analysis were released May 15 as part of the ... Oncology. , Researchers found that 95 percent of ...
... Shandong, China, May 16 /Xinhua-PRNewswire-FirstCall/ --,Shengtai Pharmaceutical, Inc. ... a leading manufacturer and distributor,of high-quality, pharmaceutical grade ... the three months ended March 31, 2008., ... -- Sales increased 64.8% to $20.7 million ...
... Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ) announced today that ... presentation at two,upcoming investor conferences., Mr. Myers will ... in London at 9:30 a.m. BST (4:30 a.m. EDT) ... 2008 Mr. Myers will present at the FBR Capital,Markets ...
... China Yingxia,International, Inc. (OTC Bulletin Board: CYXI) ("China ... nutraceutical industry engaged in the,development, manufacture and distribution ... products in the People,s Republic,of China ("PRC"), today ... March 31, 2008., First Quarter 2008 ...
... anti-inflammatory medication also known by the trade name Celebrex, ... proliferation measurement of precancerous lesions in the lung, according ... D. Anderson Cancer Center. This finding demonstrates the significance ... at higher risk of developing the disease. , The ...
Cached Medicine News:Health News:Medical College of Wisconsin researchers identify proteins that help develop mammalian hearts 2Health News:Adding epratuzumab to standard therapy 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Third Quarter Results of Fiscal Year 2008 12Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3
Used to introduce large devices for vascular intervention....
Used to introduce large devices for vascular intervention....
Used to introduce balloon, closed and non-tapered end catheters or other devices for intervention....
Used to introduce balloon, closed and non-tapered end catheters and other devices for intervention....
Medicine Products: